The impacts of menopausal hormone therapy on longer-term health consequences of ovarian hormone deficiency

References

• Khosla S, Melton LJ, 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441–451.
   PubMed Web of Science ®Google Scholar
• Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776.
   PubMed Web of Science ®Google Scholar
• Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol. 2012;11(1):82–91.
   PubMed Web of Science ®Google Scholar
• Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an international menopause society white paper. Climacteric. 2020;23(5):426–446.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women’s health initiative randomized trial. JAMA. 2003;290(13):1729–1738.
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res. 2006;21(6):817–828.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Marian Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the women’s health initiative: a randomized trial. JAMA. 2003;289(20):2673–2684.
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the women’s health initiative. Circulation. 2006;113(20):2425–2434.
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s health initiative memory study. JAMA. 2004;291(24):2947–2958.
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;3: CD002229.
   PubMed Web of Science ®Google Scholar
• LeBlanc ES, Janowsky J, Chan BK, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285(11):1489–1499.
   PubMed Web of Science ®Google Scholar
• L'Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013;16(Suppl 1):44–53.
   PubMed Web of Science ®Google Scholar
• Komulainen M, Kröger H, Tuppurainen MT, et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int. 2000;11(3):211–218.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84(9):3076–3081.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Lee DY, Park MC, et al. Effects of combination therapy of alendronate and hormonal therapy on bone mineral density in postmenopausal Korean women: multicenter, randomized controlled clinical trial. J Korean Med Sci. 2017;32(6):992–998.
   PubMed Web of Science ®Google Scholar
• Min YK, Lee DY, Suk-Joo Choi SJ, et al. Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial. Menopause. 2013;20(7):761–766.
   PubMed Web of Science ®Google Scholar
• Lorentzon M, Johansson H, Harvey NC, et al. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the women’s health initiative hormone therapy trials. Osteoporos Int. 2022;33(11):2297–2305.
   PubMed Web of Science ®Google Scholar
• Park CW, Lim SJ, Moon YW, et al. Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial. Climacteric. 2021;24(4):408–414.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583–1587.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Oh WJ, Kessel B, et al. 17Beta-estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause. 2001;8:58–64.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Kang YH, Oh WJ, et al. Effects of 17β-Estradiol on the plasminogen activator system in vascular smooth muscle cells treated with lysophophatidylcholine. J Menopausal Med. 2020;26(1):9–17.
   PubMedGoogle Scholar
• Yoon BK, Kang YH, Oh WJ, et al. 17β-Estradiol Inhibits Lysophosphatidylcholine-Induced apoptosis in cultured vascular smooth muscle cells. J Menopausal Med. 2020;26(1):1–8.
   PubMedGoogle Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47(7):1734–1741.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Sung J, Song YM, et al. Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial. Clin Hypertens. 2021;27(1):18.
   PubMedGoogle Scholar
• Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate alzheimer disease: a randomized controlled trial. JAMA. 2000;283(8):1007–1015.
   PubMed Web of Science ®Google Scholar
• Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001;57(4):605–612.
   PubMed Web of Science ®Google Scholar
• Maki PM, Gast MJ, Vieweg AJ, et al. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology. 2007;69(13):1322–1330.
   PubMed Web of Science ®Google Scholar
• Berent-Spillson A, Briceno E, Pinsky A, et al. Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology. 2015;59:25–36.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Kim DK, Kang Y, et al. Hormone replacement therapy in women with Alzheimer’s disease: a randomized, prospective study. Fertil Steril. 2003;79(2):274–280.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Chin J, Kim JW, et al. Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial. Menopause. 2018;25(8):870–876.
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim EH. Citation discovery tools for conducting adaptive meta-analyses to update systematic reviews. J Prev Med Public Health. 2016;49(2):129–133.
   PubMedGoogle Scholar
• Bae JM, Yoon BK. The role of menopausal hormone therapy in reducing all-cause mortality in postmenopausal women younger than 60 years: an adaptive meta-analysis. J Menopausal Med. 2018;24(3):139–142.
   PubMedGoogle Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74–79.
   PubMed Web of Science ®Google Scholar
• Cherry N, McNamee R, Heagerty A, et al. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG. 2014;121(6):700–705; discussion 705.
   PubMedGoogle Scholar
• Stute P, Stadler A, Heufelder A. The impact of menopausal hormone therapy on overall mortality – a comprehensive review. Climacteric. 2020;23(5):447–459.
   PubMed Web of Science ®Google Scholar
• Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17β-estradiol therapy and amyloid-β deposition. J Alzheimers Dis. 2016;53(2):547–556.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260.
   PubMed Web of Science ®Google Scholar
• Schneider HPG, Birkhäuser M. Quality of life in climacteric women. Climacteric. 2017;20(3):187–194.
   PubMed Web of Science ®Google Scholar
• American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117:1038–1041.
   PubMed Web of Science ®Google Scholar
• Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277(14):1140–1147.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pickar JH, Stevenson JC, et al. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254:282–290.
   PubMed Web of Science ®Google Scholar